Tissue Regenix Group
Medical Equipment ManufacturingEngland, United Kingdom51-200 Employees
Tissue Regenix Group is a medical devices company based in Leeds, England, operating in the regenerative medicine space. It began in 2006 as a spin-out from the University of Leeds and relies on its dCELL technology to remove DNA and cellular material from animal and human soft tissue, producing acellular scaffolds used to repair damaged tissues while aiming to minimize immune rejection. Its applications span sports medicine, heart valve replacement, and wound care, addressing clinical needs with regenerative tissue solutions. The business has pursued international growth through a United States subsidiary established in 2012 (later rebranded) and a joint venture in Rostock, Germany. It expanded its regenerative offerings with the 2017 acquisition of CellRight Technologies, adding osteobiologic and wound care capabilities. A notable recent development is the appointment of Kirsten Lund as chief financial officer and board member in October 2025.
1-888-653-2347 
support@leadiq.com 
